The antiobesity drug Orlistat induces cytotoxic effects, suppresses Her-2/neu (erbB-2) oncogene overexpression, and synergistically interacts with trastuzumab (Herceptin™) in chemoresistant ovarian cancer cells

J. A. Menendez, L. Vellon, R. Lupu

Research output: Contribution to journalArticle

26 Scopus citations
Original languageEnglish (US)
Pages (from-to)219-221
Number of pages3
JournalInternational Journal of Gynecological Cancer
Volume16
Issue number1
DOIs
StatePublished - Jan 1 2006

Keywords

  • Her-2/neu
  • Orlistat
  • Ovarian cancer

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this